Introduction:Hepatitis C Virus (HCV) in kidney transplant recipients (KTRs) has an increased risk of mortality and morbidity, and can have complications that affect graft survival. Clearance of HCV or drugs used to achieve clearance could have any influence in the renal graft function. Impact of the new direct-acting antivirals (DAAs) on renal graft function is limited.
Materials and Methods:We analysed treatment results with DAAs in KTRs, regarding effectiveness, tolerance, impact on immunosuppression, and renal function. Each patient was follow-up prospectively every two weeks until finished the treatment.
Results:Eighteen patients (61% were male and with mean age of 58,39 ± 9,6 years) genotype of HCV more frequent was G1B (N=10;56%). Antiviral treatment: 3 patients (16.7%) with the combo of AbbVie and the rest of the patient with a triple-combination including in all the case sofosbuvir. There was not significant change in the proteinuria before and after therapy, however, the renal function seems to improve slightly along the treatment. Glomerular filtration rate (GFR) before treatment were stable (65 ± 19,2 ml/min ml/min pretreatment and 67,5 ± 21,6 ml/min 12 weeks before start treatment, p>0.05) and improve slightly after treatment (70 ± 24,2 ml/min, p≤0.05). Creatinine levels follow the same pattern (1,15 ± 0,3 mg/dl at 12 weeks pretreatment vs 1.2 ± 0.2mg/dl at basal visit, p>0.05 and 1,16 ± 0,2mg/dl at final visit, p≤0.05).
Conclusion:Treatment with DDAs in KTRs not only not impairs renal grafting but also, with strict control of drug levels, could improve it after treatment.